Mehlman High Yield Risk Factors Practice Test 2026 – Complete Exam Prep

Metformin as first-line therapy targets the key factor driving long-term health outcomes in type 2 diabetes: hyperglycemia. An HbA1c of 7% shows suboptimal glucose control, and strengthening glycemic control with metformin reduces hepatic glucose production and improves insulin sensitivity. This tends to lower the risk of microvascular complications (retinopathy, nephropathy, neuropathy) and is associated with favorable long-term outcomes, including reduced mortality, especially in younger patients who have many years ahead for complications to develop. Metformin also has advantages like limited hypoglycemia risk and potential modest weight loss, which further benefits overall health.

While starting a statin would lower cardiovascular risk and an ACE inhibitor could protect kidney function or lower blood pressure, neither addresses the primary driver of morbidity in this patient as directly as improving glycemic control with metformin at this stage. An exercise program is valuable for overall health and glycemic control, but in this specific scenario, initiating metformin provides the strongest impact on reducing long-term morbidity by tackling the diabetes itself.